A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers

NCT02920931 | Completed Phase 1

• 1 other identifier: BR-TND-CT-101
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers.

Conditions

Hepatitis

Outcome Measures

Primary Outcomes (2)

• Maximum observed concentration(Cmax) of Tenofovir

  0~72 hour after medication

• Area under the curve(AUCt) of Tenofovir

  0~72 hour after medication

Study Arms (2)

A

EXPERIMENTAL

1. st period: Tenofovir disoproxil fumarate 2. nd period: Tenofovir Disoproxil

Drug: Tenofovir disoproxil

B

ACTIVE COMPARATOR

1. st period: Tenofovir disoproxil 2. nd period: Tenofovir Disoproxil fumarate

Drug: Tenofovir disoproxil

Interventions

Tenofovir disoproxil DRUG

A; B

Eligibility Criteria

• Age: 19 Years - 45 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male subject, aged 19- 45 years at screening.
• Body weight of ≥ 55 kg and within ± 20% of ideal body weight (IBW)(kg) = {height (cm) - 100} \* 0.9
• No morbid symptom or sign, based on physical examination, with no innate or chronic disease.
• Subject that is considered appropriate for participating in the study by an investigator, based on clinical laboratory test (hematology, clinical chemistry, urinalysis) that is performed according to the characteristics of investigational drugs.
• Subjects must be able to listen to and understand the detailed statement of informed consent, and willing to decide to participate in the study, follow the study directions and provide written informed consent.

You may not qualify if:

• A clinically significant disease or history in hepatobiliary system, kidney, digestive system, respiratory system, hemato-oncological system, endocrine system, neuro-psychiatric system, musculo-skeletal system, immune system, otorhinolaryngological system or cardiovascular system.
• A history of gastrointestinal system disorder(i.e, Crohn's disease, ulcer, acute or chronic pancreatitis) or surgery (excluding simple appendectomy or herniorrhaphy) that may affect absorption of investigational drugs.
• A history of hypersensitivity to investigational drugs and its additives or clinically significant hypersensitivity to any other drug.
• Galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption and any other hereditary disorder.
• Vital sign measured in sitting position meets any one of following results; systolic blood pressure \> 140 mmHg or \<100 mmHg, diastolic blood pressure \> 90 mmHg or \<60 mmHg, pulse ≥ 100 times/min.
• Aspartate aminotransferase(AST) or Alanine aminotransaminase(ALT) \> 2 times upper normal limit, or Total bilirubin \> 2 times upper normal limit.
• Renal disorder (Creatinine clearance \< 50 mL/min, calculated by Cockcroft-Gault formula)
• Positive in serologic tests (RPR Ab(VDRL), HBsAg, hepatitis C virus (HCV) Ab, anti HIV(AIDS))
• History of drug abuse, or positive in drug screening test.
• Use of inducer or inhibitor of metabolic enzymes for drugs like barbiturate.
• Use of any prescribed drugs or herbal remedies within 2 weeks, or use of any over-the-counter medication within 1 week prior to the first administration of investigational drug, and this will affect this study or the safety of the subjects at discretion of study investigator.
• Participation in another clinical trial or a bioequivalent study within 3 months prior to the first administration of investigational drug (The finish time of previous study is the day of the last administration of study drug)
• Whole blood donation within 2 months or component donation within 1 month, prior to the first administration of investigational drug, or transfusion within 1 month prior to the first administration of investigational drug.
• Prolonged excessive alcohol consumption (\>21 units/week, 1 unit=10g of pure alcohol), or subjects who can not abstain from drinking from 24 hours prior to hospitalization until the discharge.
• Smoking more than 10 cigarettes per day, excessive caffeine consumption (example: instant coffee \> 5 cups/day)

Sponsors & Collaborators

• Boryung Pharmaceutical Co., Ltd: lead

Study Sites (1)

ChungNam university hospital

Jungnam, South Korea

Location

MeSH Terms

Conditions

Hepatitis

Interventions

Tenofovir

Condition Hierarchy (Ancestors)

Liver Diseases; Digestive System Diseases

Intervention Hierarchy (Ancestors)

Organophosphonates; Organophosphorus Compounds; Organic Chemicals; Adenine; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Jang Hee Hong, PhD

  Chungnam National University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 29, 2016
• First Posted: September 30, 2016
• Study Start: February 1, 2016
• Primary Completion: April 1, 2016
• Study Completion: April 1, 2016
• Last Updated: January 26, 2017

Record last verified: 2016-12

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)